Key Highlights
- Ossama Eissa joins Cellares as COO to expand global cell therapy manufacturing.
- Eissa brings over 20 years of experience from Novartis, Lonza, and Legend Biotech.
- Cellares’ IDMO Smart Factories to increase production and accessibility of cell therapies.
- Cellares’ Cell Shuttle™ and Cell Q™ platforms enhance manufacturing and quality control.
- Global expansion targets U.S., Europe, Japan, and beyond to meet cell therapy demand.
Source: Business Wire
Notable Quotes
- “Joining Cellares is an opportunity to address one of the biggest challenges in healthcare today: making cell therapies accessible to all of those who need them.” — Ossama Eissa, COO at Cellares
- “With Ossama’s leadership, we are scaling worldwide production while redefining how cell therapies are made — faster, more reliably, and at scale.” — Fabian Gerlinghaus, Co-founder and CEO at Cellares
SoHC's Take
The appointment of Ossama Eissa as COO underscores Cellares’ commitment to addressing critical bottlenecks in cell therapy manufacturing. Eissa’s proven track record with CAR-T therapies at Legend Biotech, Lonza Biologics, and Novartis aligns perfectly with Cellares’ growth objectives, particularly as the global demand for cell therapies intensifies. His leadership will be instrumental as Cellares builds out its IDMO Smart Factories and scales the deployment of its proprietary Cell Shuttle™ and Cell Q™ platforms worldwide, setting a new standard for reliable, scalable cell therapy production and quality control.
